Patents by Inventor Charles Z. Ding

Charles Z. Ding has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PYRIMIDINYL GROUP-CONTAINING TRICYCLIC COMPOUND SERVING AS C-MET INHIBITOR
    Publication number: 20230056559
    Abstract: Disclosed are a pyrimidinyl group-containing tricyclic compound and applications thereof in preparing a cancer-treating medicament. Specifically disclosed are a compound as represented by formula (I), a pharmaceutically acceptable salt of same, or an isomer thereof.
    Type: Application
    Filed: January 22, 2020
    Publication date: February 23, 2023
    Inventors: Xile LIU, Charles Z. DING, Shuhui CHEN, Lihong HU, Haiwen WAN
  • BIARYL COMPOUND AS PAN-RAF KINASE INHIBITOR
    Publication number: 20230046018
    Abstract: Disclosed is a biarylamide compound as a Pan-RAF kinase inhibitor, and specifically disclosed are a compound as shown in formula (III) and a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: December 4, 2020
    Publication date: February 16, 2023
    Inventors: Charles Z. DING, Xile LIU, Shuhui CHEN, Lihong HU, Chengliang ZHOU
  • SULFONYLUREA RING SUBSTITUTED MONOCYCLIC beta-LACTAM ANTIBIOTICS
    Publication number: 20230037556
    Abstract: Sulfonylurea ring substituted monocyclic ?-lactam antibiotics, and specifically relating to a compound represented by formula (I), a pharmaceutically acceptable salt or a stereoisomer thereof, and an application thereof in the preparation of medicaments for treating diseases related to bacterial infections.
    Type: Application
    Filed: November 20, 2020
    Publication date: February 9, 2023
    Inventors: Wei LUO, Zhigang HUANG, Charles Z. DING, Jian LI, Shuhui CHEN
  • Anti-HBVtetrahydroisoxazolo[4,3-c]pyridine compounds
    Patent number: 11572372
    Abstract: Disclosed are a class of anti-HBV tetrahydroisoxazolo[4,3-c]pyridine compounds and pharmaceutically acceptable salts thereof or isomers thereof, the compounds being represented by the formula (I).
    Type: Grant
    Filed: November 16, 2018
    Date of Patent: February 7, 2023
    Assignee: Medshine Discovery Inc.
    Inventors: Lifang Wu, Fei Sun, Jinhua Du, Charles Z. Ding, Shuhui Chen, Xiquan Zhang, Hongjiang Xu, Ling Yang
  • APPLICATION OF COMPOUND IN DRUG PREPARATION
    Publication number: 20230022708
    Abstract: The present invention relates to a use of a compound represented by formula (I) and a pharmaceutically acceptable salt thereof in the field of pharmaceutics, and in particluar an application thereof in the preparation of a drug for treating pneumonia.
    Type: Application
    Filed: December 18, 2020
    Publication date: January 26, 2023
    Inventors: XiaWei WEI, Zhigang HUANG, Charles Z. DING, Yuquan WEI
  • CRYSTAL FORM OF HEPATITIS B SURFACE ANTIGEN INHIBITOR AND APPLICATION THEREOF
    Publication number: 20220402939
    Abstract: Disclosed is a crystal form of a hepatitis B surface antigen inhibitor and a preparation method, and an application of the crystal form in the preparation of the hepatitis B surface antigen inhibitor.
    Type: Application
    Filed: September 18, 2020
    Publication date: December 22, 2022
    Inventors: Zhe CAI, Fei SUN, Charles Z. DING
  • Pyrimidine compound acting on EGFR and ERBB2
    Patent number: 11530196
    Abstract: Disclosed is a pyrimidine compound acting on an EGFR exon 20 insertion mutation and an ERBB2 exon 20 insertion mutation or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 24, 2020
    Date of Patent: December 20, 2022
    Assignee: CHINA RESOURCES PHARMACEUTICAL HOLDINGS COMPANY LIMITED
    Inventors: Charles Z. Ding, Lu Zhang, Xile Liu, Lihong Hu, Wen Jiang, Jian Li, Shuhui Chen
  • TETRACYCLIC COMPOUND USED AS CDC7 INHIBITOR
    Publication number: 20220389026
    Abstract: A tetracyclic compound as a Cdc7 inhibitor. Specifically disclosed is a compound represented by formula (I), an isomer thereof, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 20, 2020
    Publication date: December 8, 2022
    Inventors: Lun Lu, Gang Li, Lihong Hu, Charles Z. Ding, Shuhui Chen
  • SEVEN-MEMBERED HETEROCYCLIC DERIVATIVE ACTING AS KRAS G12C MUTANT PROTEIN INHIBITOR
    Publication number: 20220372036
    Abstract: A class of KRAS G12C mutant protein inhibitors, specifically disclosing the compound shown in formula (I), and an isomer and a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: June 24, 2020
    Publication date: November 24, 2022
    Inventors: Charles Z. Ding, Shuhui Chen
  • Crystal form of c-MET inhibitor and salt form thereof and preparation method therefor
    Patent number: 11465986
    Abstract: Disclosed are a crystal form of a c-MET inhibitor and a salt form thereof and a preparation method therefor. Specifically involved are the compound as shown in formula (I), and a salt form and a crystal form thereof, and also included is the use of the crystal form and the salt form in the preparation of medicines for treating cancers.
    Type: Grant
    Filed: April 26, 2019
    Date of Patent: October 11, 2022
    Assignee: FUJIAN AKEYLINK BIOTECHNOLOGY CO., LTD.
    Inventors: Xiongbin Xu, Gang Li, Ting Yao, Kun Wang, Lihong Hu, Charles Z. Ding
  • Monocyclic ?-lactam compound for treating bacterial infection
    Patent number: 11459323
    Abstract: Disclosed are a class of new monocyclic ?-lactam compounds, an isomer thereof or pharmaceutically acceptable salts thereof, and a pharmaceutical composition comprising the compounds, and the use of same in preparing drugs for treating diseases associated with bacterial infection. Specifically disclosed are the compounds as shown in formula (I?) and formula (II?), isomers thereof or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: January 29, 2019
    Date of Patent: October 4, 2022
    Assignee: MEDSHINE DISCOVERY INC.
    Inventors: Lianghu Gu, Wei Luo, Zhigang Huang, Charles Z. Ding, Cheng Li, Shuhui Chen
  • Preparation Method for Oxazepine Compound
    Publication number: 20220306648
    Abstract: Provided is a preparation method for an oxazepine compound, and specifically disclosed are a preparation method for a compound of formula (I) and an intermediate of same.
    Type: Application
    Filed: July 28, 2020
    Publication date: September 29, 2022
    Inventors: Yanbin HU, Fei SUN, Charles Z. DING
  • Pyridone-pyrimidine derivative acting as KRASG12C mutein inhibitor
    Patent number: 11453667
    Abstract: Provided are a class of KRAS G12C mutein inhibitors, which relate in particular to a compound represented by formula (I), an isomer thereof, and a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: September 27, 2022
    Assignee: MEDSHINE DISCOVERY INC.
    Inventors: Yaxian Cai, Zhaobing Xu, Hailong Yang, Shiqi Han, Guoping Hu, Lihong Hu, Charles Z. Ding, Jian Li, Shuhui Chen
  • PYRIMIDINE COMPOUND ACTING ON EGFR AND ERBB2
    Publication number: 20220289714
    Abstract: Disclosed is a pyrimidine compound acting on an EGFR exon 20 insertion mutation and an ERBB2 exon 20 insertion mutation or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: July 24, 2020
    Publication date: September 15, 2022
    Inventors: Charles Z. DING, Lu ZHANG, Xile LIU, Lihong HU, Wen JIANG, Jian LI, Shuhui CHEN
  • MACROCYCLIC DERIVATIVES AS FACTOR XIA INHIBITORS
    Publication number: 20220281868
    Abstract: Macrocyclic derivatives, preparation methods therefor and pharmaceutical compositions comprising said derivatives, and uses thereof as therapeutic agents, especially as factor XIa inhibitors and in drugs for treating and preventing thromboembolisms and other diseases. Specifically disclosed is a compound represented by formula (I), and an isomer and pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: July 23, 2020
    Publication date: September 8, 2022
    Inventors: Yaxian CAI, Xiaobing YAN, Zhe CAI, Guoping HU, Charles Z. DING, Kevin X CHEN, Jian LI, Shuhui CHEN
  • TETRACYCLIC COMPOUNDS AS CDC7 INHIBITORS
    Publication number: 20220235068
    Abstract: A new class of tetracyclic compounds acting as Cdc7 inhibitors; specifically disclosed are a compound represented by formula (I), isomers thereof, or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: May 29, 2020
    Publication date: July 28, 2022
    Inventors: Gang Li, Lun Lu, Zhibo Zhang, Lihong Hu, Charles Z. Ding, Shuhui Chen
  • CRYSTAL FORM OF C-MET/AXL INHIBITOR
    Publication number: 20220235029
    Abstract: A crystal form and a salt form of a uracil compound acting as a c-MET/AXL inhibitor and a preparation method therefor, specifically relating to the crystal form and the salt form of the compound shown in formula (I), and also comprising an application of the crystal form and the salt form in the preparation of drugs for the treatment of tumours.
    Type: Application
    Filed: May 22, 2020
    Publication date: July 28, 2022
    Inventors: Gang LI, Kun WANG, Lihong HU, Charles Z. DING
  • ANTIBACTERIAL AMINOGLYCOSIDE DERIVATIVES
    Publication number: 20220227802
    Abstract: Disclosed are a new class of antibacterial aminoglycoside derivatives, pharmaceutical compositions containing such compounds, and application thereof in the preparation of drugs for treating diseases related to bacterial infections. Specifically disclosed are a compound represented by formula (II), pharmaceutically acceptable salts thereof, and isomers thereof.
    Type: Application
    Filed: May 29, 2020
    Publication date: July 21, 2022
    Inventors: Dongdong TANG, Zhigang HUANG, Cheng LI, Charles Z. DING, Shuhui CHEN
  • Aryl-phosphorus-oxygen compound as EGFR kinase inhibitor
    Patent number: 11390625
    Abstract: Disclosed is a class of new aryl-phosphorus-oxygen compounds as shown in formula (I) as EGFR kinase inhibitors, and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: July 19, 2018
    Date of Patent: July 19, 2022
    Assignee: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Lingyun Wu, Xile Liu, Charles Z. Ding, Shuhui Chen, Lihong Hu, Lele Zhao, Wei Pan, Guoping Hu, Jian Li, Ning Zhao, Jun Zhao
  • MACROCYCLIC DERIVATIVES ACTING AS XIA FACTOR INHIBITOR
    Publication number: 20220204508
    Abstract: Disclosed are a class of macrocyclic derivatives, a preparation method therefor, a pharmaceutical composition containing the derivatives, and the use thereof as therapeutic agents, particularly as XIa factor inhibitors and in the preparation of a drug for treating and preventing thromboembolisms and other diseases. Particularly disclosed are compounds shown by formula (I), an isomer thereof and a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: April 15, 2020
    Publication date: June 30, 2022
    Applicant: MEDSHINE DISCOVERY INC.
    Inventors: Yaxian Cai, Xiaobing Yan, Ting Wang, Chengde Wu, Charles Z. Ding, Shuhui Chen